Ads
related to: dr reddy's laboratories locations near me current
Search results
Results From The WOW.Com Content Network
The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed.They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". [8]
Real estate in Bachupally is one of the major sector in the area contributing to the economy. [3] It is also referred to as the pharmaceutical hub of Hyderabad, as it houses R&D centers of top pharma manufacturers including Dr. Reddy's lab, Aurobindo Pharma, and SMS Pharma.
Ranbaxy competed with the maker of brand-name Zocor, Merck & Co.; IVAX Corporation (which was acquired by and merged into Teva Pharmaceutical Industries Ltd.), which has 180-day exclusivity at strengths other than 80 mg; and Dr. Reddy's Laboratories and India, whose authorized generic version (licensed by Merck) is exempt from exclusivity.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Dr. Reddy's Laboratories Limited (NSE:DRREDDY) with a market-capitalization of ₹432b, rarely draw ...
For premium support please call: 800-290-4726 more ways to reach us
Benzex was later acquired by Dr. Reddy's Laboratories. He then left the industry to focus on construction. In 1990, he reemerged in pharmaceuticals and became the CEO and MD of Cheminor Drugs Ltd. In 2001, Cheminor Drugs merged with Dr. Reddy's Laboratories [3] and Prasad took over as the vice-chairman and CEO of the merged entity. [4]
Kallam Satish Reddy is an Indian business executive and current Chairman of Dr. Reddy's Laboratories. [ 2 ] [ 3 ] Reddy joined Dr. Reddy's Laboratories in 1993 as executive director. Elevated to the role of Managing Director in 1997, he led the company's transition from a manufacturer of active pharmaceutical ingredients to one with a diverse ...
The warning letter summarized significant deviations from current good manufacturing practices (cGMP) for active pharmaceutical ingredients (API). On 7 October 2019, Aurobindo said it received seven observations from the USFDA for its unit-7 formulation plant in Telangana, with regard to potentially misleading documentation. [ 20 ]